CHRS News and Press, Coherus BioSciences Inc.

2026-03-09 20:58:47 ET More on Coherus BioSciences Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114 Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare C...

2026-03-09 20:57:57 ET Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call March 9, 2026 4:30 PM EDT Company Participants Carrie Graham - Vice President of Investor Relations & Advocacy Dennis Lanfear - Chairman, President & CEO Theresa Lavallee - Chief Dev...

2026-03-09 16:23:51 ET More on Coherus BioSciences Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114 Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Coherus Oncology: A Two-Pronged March With...

– LOQTORZI ® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in year ending cash, cash equivalent...

New Fortress Energy Inc. (NFE) is expected to report $-1.08 for Q4 2025 Design Therapeutics Inc. (DSGN) is expected to report $-0.38 for Q4 2025 Beta Technologies Inc. Class A (BETA) is expected to report $-0.52 for Q4 2025 Yext Inc. (YEXT) is expected to report $0.06 for Q4 2026 ...

2026-03-08 17:35:32 ET More on Coherus BioSciences Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114 Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Coherus Oncology: A Two-Pronged March With...

2026-03-08 08:07:45 ET Despite a relatively light earnings calendar, the upcoming earnings week will offer investors a broad look across multiple sectors, from technology and EVs to retail, mining, and biotech, as several notable companies report results. ... Read the full articl...

REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus...

2026-02-20 03:35:10 ET The last time I spoke about Coherus Oncology ( CHRS ) it was with respect to a Seeking Alpha article entitled " Coherus: Biosimilar And Immuno-Oncology Pipeline Setup Could Pay Off ". With respect to this article, I noted that the company was geari...

–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Companyȁ...